Peter Habenberger

2.0k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

Peter Habenberger is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Peter Habenberger has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Immunology. Recurrent topics in Peter Habenberger's work include Chronic Lymphocytic Leukemia Research (3 papers), Immune cells in cancer (3 papers) and Cancer-related Molecular Pathways (3 papers). Peter Habenberger is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Immune cells in cancer (3 papers) and Cancer-related Molecular Pathways (3 papers). Peter Habenberger collaborates with scholars based in Germany, Norway and Switzerland. Peter Habenberger's co-authors include Axel Choidas, Bert Klebl, Matthew Cotten, Jan Eickhoff, Henrik Daub, Josef Wissing, Stephanie Blencke, Peter Nußbaumer, Sascha Menninger and Gabriel Sollberger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Peter Habenberger

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gasdermin D plays a vital role in the generation of neutrophil extracellular traps

2018 571 citations Gabriel Sollberger, Axel Choidas et al. Science Immunology profile →

Peers

Countries citing papers authored by Peter Habenberger

Since Specialization

Citations

This map shows the geographic impact of Peter Habenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Habenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Habenberger more than expected).

Fields of papers citing papers by Peter Habenberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Habenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Habenberger. The network helps show where Peter Habenberger may publish in the future.

Co-authorship network of co-authors of Peter Habenberger

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Habenberger. A scholar is included among the top collaborators of Peter Habenberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Habenberger. Peter Habenberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland 2023 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Anke Unger, Peter Habenberger, (unknown), Jan Eickhoff, Bert Klebl, Eirik Sundby, Bård Helge Hoff	1
2	Negishi Cross‐Coupling in the Preparation of Benzyl Substituted Pyrrolo[2,3‐d]pyrimidine Based CSF1R Inhibitors 2023 ·European Journal of Organic Chemistry ·(unknown), (unknown), Anke Unger, Peter Habenberger, Alexander Wolf, Jan Eickhoff, Bert Klebl, (unknown), Geir Bjørkøy, Eirik Sundby, Bård Helge Hoff	4
3	Synthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form 2023 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anke Unger, Peter Habenberger, Alexander Wolf, Geir Bjørkøy, Clare Pridans, Jan Eickhoff, Bert Klebl, Bård Helge Hoff, Eirik Sundby	6
4	White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy 2022 ·Cancers ·Edgar Dahl, (unknown), Peter Habenberger, Axel Choidas, Michael Rose, Bert Klebl	12
5	Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia 2020 ·Therapeutic Advances in Hematology ·Patricia Johansson, (unknown), Ludger Klein‐Hitpaß, Anke K. Bergmann, Michael Möllmann, Sascha Menninger, Peter Habenberger, Bert Klebl, Jens T. Siveke, Ulrich Dührsen, Axel Choidas, Jan Dürig	9
6	Gasdermin D plays a vital role in the generation of neutrophil extracellular traps breakdown → 2018 ·Science Immunology ·Gabriel Sollberger, Axel Choidas, Garth L. Burn, Peter Habenberger, Raffaella Di Lucrezia, (unknown), Sascha Menninger, Jan Eickhoff, Peter Nußbaumer, Bert Klebl, Renate Krüger, Alf Herzig, Arturo Zychlinsky	571
7	SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia 2018 ·Blood Cancer Journal ·Patricia Johansson, Ludger Klein‐Hitpaß, Axel Choidas, Peter Habenberger, (unknown), Baek Kim, Anke K. Bergmann, René Scholtysik, (unknown), Anna Lollies, Reiner Siebert, Thorsten Zenz, Ulrich Dührsen, Ralf Küppers, Jan Dürig	44
8	Discovery of a Novel Inhibitor of the Hedgehog Signaling Pathway through Cell‐based Compound Discovery and Target Prediction 2017 ·Angewandte Chemie ·Lea Kremer, Carsten Schultz‐Fademrecht, Matthias Baumann, Peter Habenberger, Axel Choidas, Bert Klebl, (unknown), Hans R. Schöler, Jared Sterneckert, Slava Ziegler, Gisbert Schneider, Herbert Waldmann	7
9	Discovery of a Novel Inhibitor of the Hedgehog Signaling Pathway through Cell‐based Compound Discovery and Target Prediction 2017 ·Angewandte Chemie International Edition ·Lea Kremer, Carsten Schultz‐Fademrecht, Matthias Baumann, Peter Habenberger, Axel Choidas, Bert Klebl, (unknown), Hans R. Schöler, Jared Sterneckert, Slava Ziegler, Gisbert Schneider, Herbert Waldmann	20
10	Identification of an (−)‐englerin A analogue, which antagonizes (−)‐englerin A at TRPC1/4/5 channels 2017 ·British Journal of Pharmacology ·Hussein N. Rubaiy, Tobias Seitz, (unknown), Axel Choidas, Peter Habenberger, Bert Klebl, Klaus Dinkel, Peter Nußbaumer, Herbert Waldmann, Mathias Christmann, David J. Beech	18
11	Abstract 2823: Identification of highly selective inhibitors of cyclin-dependent kinase 12 2016 ·Cancer Research ·Axel Choidas, Carsten Schultz‐Fademrecht, (unknown), Peter Habenberger, Uwe Koch, Jan Eickhoff, (unknown), Peter Nußbaumer, Matthias Geyer, Bert Klebl	1
12	Total Synthesis and Biological Evaluation of (−)‐Englerin A and B: Synthesis of Analogues with Improved Activity Profile 2011 ·Angewandte Chemie International Edition ·Lea Radtke, Matthieu Willot, Hongyan Sun, Slava Ziegler, (unknown), Carsten Strohmann, Roland Fröhlich, Peter Habenberger, Herbert Waldmann, Mathias Christmann	75
13	Total Synthesis and Biological Evaluation of (−)‐Englerin A and B: Synthesis of Analogues with Improved Activity Profile 2011 ·Angewandte Chemie ·Lea Radtke, Matthieu Willot, Hongyan Sun, Slava Ziegler, (unknown), Carsten Strohmann, Roland Fröhlich, Peter Habenberger, Herbert Waldmann, Mathias Christmann	32
14	Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors 2004 ·Molecular & Cellular Proteomics ·Josef Wissing, Klaus Godl, Dirk Brehmer, Stephanie Blencke, Martina Weber, Peter Habenberger, Matthias Stein-Gerlach, Andrea Missio, Matthew Cotten, Stefan Müller, Henrik Daub	65
15	RICK Activates a NF-κB-dependent Anti-human Cytomegalovirus Response 2004 ·Journal of Biological Chemistry ·Jan Eickhoff, (unknown), Matthias Stein-Gerlach, (unknown), (unknown), Peter Habenberger, Stefan Müller, Bert Klebl, Manfred Marschall, Thomas Stamminger, Matthew Cotten	31
16	An efficient proteomics method to identify the cellular targets of protein kinase inhibitors 2003 ·Proceedings of the National Academy of Sciences ·Klaus Godl, Josef Wissing, Alexander Kurtenbach, Peter Habenberger, Stephanie Blencke, Heidrun Gutbrod, (unknown), Matthias Stein-Gerlach, Andrea Missio, Matthew Cotten, Henrik Daub	283
17	Identification of SRPK1 and SRPK2 as the Major Cellular Protein Kinases Phosphorylating Hepatitis B Virus Core Protein 2002 ·Journal of Virology ·Henrik Daub, Stephanie Blencke, Peter Habenberger, Alexander Kurtenbach, (unknown), Josef Wissing, Axel Ullrich, Matthew Cotten	123

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact